ABOUT SAMSUNG BIOLOGICS
Samsung Biologics is a full-service provider offering development and cGMP manufacturing services. We deliver a broad range of services from development and manufacturing to fill and finish, covering both clinical molecules and commercial products. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), and clinical and commercial bulk cGMP manufacturing of drug substance and drug product. We also provide quality assurance and quality control services, as well as worldwide regulatory compliance standards & support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.
CONTACT INFORMATION
Samsung Biologics
300 Songdo Bio Way, Yeonsu-gu
Incheon, 21987
KOREA, REPUBLIC OF
Phone: +82 32 455 3114
Contact: Jinyong Kim
BROCHURES
- Link Your Antibody To Its Fullest Potential
- Trusted End-To-End CDMO Partner For Your Journey
- Capacity To Secure Your Success
- Take The Right Step To Advance Your Molecule
- Super Plant 4
- Antibody Drug Conjugates: Link Your Antibody To Its Fullest Potential
- Plant 5 - Dream Plant: Within Your Reach. Built For Your Success.
- Why Samsung Biologics?
- Samsung Biologics: A CDMO Delivering Innovation And Capacity
- Aseptic Fill/Finish Service
- The Power Of One: mRNA Services
- Leveraging Proprietary CDO Platforms
FEATURED ARTICLES
- Streamlining Single-Use Assemblies In The Bulk-Fill Step Of Downstream Processing
- Reducing ADC Timelines With Integrated Development And Manufacturing Services
- Accelerating The Development And Production Of High-Quality Bispecific Antibodies
- Optimizing Sialic Acid Clone Screening Through A High-Throughput Lectin Assay
- Addressing And Adapting To Evolving mRNA Market Trends
- β-Glucan As A Process-Related Impurity In Biopharmaceuticals
- Monoclonal Antibody Manufacturing: Build Or Outsource?
- Biopharma Tech Transfer: Facility Fit And Process Gap Assessments
- Choose A Partner That Integrates Market Intelligence For Aseptic Fill/Finish
- Beyond COVID-19: How Localization Strengthens Supply Chains
- The Challenges Of Biopharmaceutical Quality
- Ensuring A Successful Technology Transfer
- Plan Your CDMO Search On A Foundation For Long-Term Success
- Overcome Data Integrity Challenges In Biopharma Production
- Embracing Necessary Digital Transformation In Biomanufacturing
- Setting The Right Goals: Go Digital, Not Paperless
- Ensuring Stability And Safety In Aseptic Fill/Finish Manufacturing
- Considerations For Successful Upstream Manufacturing Process Scale-Up
- Implementing A More Robust Post-Pandemic Supply Chain
- CDMO Expertise Accelerates Biologics Development, Manufacturing
WEBINARS
- Downstream Strategies To Accelerate Preclinical Development Timelines
- Continuous Manufacturing: Challenges, Advantages Of N-1 Perfusion
- Key Considerations When Outsourcing An Aseptic Fill/Finish Project To A CMO Partner
- How COVID-19 Is Redefining Drug Development And Manufacturing
- All Eyes On mRNA: Addressing Key Insights Into The Next Blockbuster
- Accelerated Tech Transfer For A COVID-19 Program
- Biopharmaceutical Process Characterization